Curcumin-95 (Curcuma longa extract)

Curcumin-95 is a standardized extract from Curcuma longa rhizome containing 95% curcuminoids, with curcumin as the dominant bioactive compound. It exerts antioxidant and anti-inflammatory effects primarily through its α,β-unsaturated β-diketone moiety, which scavenges free radicals and modulates inflammatory signaling cascades.

Origin & History

Curcumin-95 is a branded, standardized extract from the rhizomes of Curcuma longa (turmeric plant), enriched to contain ≥95% total curcuminoids. The extract is produced from turmeric root, a perennial herb native to South Asia, using solvents like ethanol or methanol to isolate the bioactive fraction.

Historical & Cultural Context

Turmeric (Curcuma longa) has been used in Ayurvedic and traditional Indian medicine for centuries as an anti-inflammatory, antimicrobial, and digestive aid. The exact duration and specific traditional medicine systems are not specified in the provided research.

Health Benefits

• Anti-inflammatory effects (evidence quality not specified in provided research)
• Antioxidant properties through α,β-unsaturated β-diketone moiety (mechanistic evidence only)
• Traditional use for digestive aid (historical evidence only)
• Antimicrobial properties (traditional use evidence only)
• Note: The provided research lacks specific clinical trial data for Curcumin-95's health benefits

How It Works

Curcumin inhibits NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation, thereby suppressing downstream pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Its α,β-unsaturated β-diketone moiety acts as a Michael acceptor, enabling direct free radical scavenging and upregulation of Nrf2-mediated antioxidant enzyme expression, including heme oxygenase-1 (HO-1) and superoxide dismutase (SOD). Additionally, curcumin inhibits cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes, reducing prostaglandin E2 and leukotriene synthesis.

Scientific Research

The provided research dossier lacks specific details on human clinical trials, RCTs, or meta-analyses for Curcumin-95, with no PubMed PMIDs included. While broader curcumin literature is mentioned to show anti-inflammatory effects, no study designs, sample sizes, or specific outcomes are detailed in these sources.

Clinical Summary

Human clinical trials on curcumin are limited by its notoriously poor oral bioavailability, with standard curcumin showing less than 1% absorption in most pharmacokinetic studies. Small randomized controlled trials (typically 30–120 participants) have reported reductions in serum CRP and IL-6 in subjects with metabolic syndrome and osteoarthritis, though effect sizes vary considerably across studies. A 2019 meta-analysis of 11 RCTs found statistically significant reductions in fasting blood glucose and LDL cholesterol, but sample sizes were generally small and follow-up periods short (8–12 weeks). Overall evidence quality is moderate at best, and larger, well-powered trials using bioavailability-enhanced formulations are needed before definitive clinical conclusions can be drawn.

Nutritional Profile

Curcumin-95 is a highly concentrated extract from Curcuma longa (turmeric root) standardized to contain approximately 95% total curcuminoids by weight. The curcuminoid fraction consists of three primary bioactive polyphenols: curcumin (curcumin I) comprising approximately 70-80% of the extract, demethoxycurcumin (curcumin II) at approximately 15-25%, and bisdemethoxycurcumin (curcumin III) at approximately 3-5%. Macronutrient content is nutritionally negligible at typical supplemental doses (250-500 mg): carbohydrates <0.5 mg, protein <0.1 mg, fat <0.1 mg. No meaningful vitamin or mineral content is present at supplemental doses. The key bioactive compound is the α,β-unsaturated β-diketone moiety responsible for antioxidant and anti-inflammatory mechanistic activity. Bioavailability is a critical limitation: native curcumin is poorly absorbed in the gastrointestinal tract due to low aqueous solubility, rapid metabolism, and swift systemic elimination, with oral bioavailability estimated at less than 1% in standard form. Peak plasma concentration after standard oral dosing is typically low (nanomolar range). Bioavailability is significantly enhanced when co-administered with piperine (black pepper extract, ~20-fold increase), or when formulated as phospholipid complexes, nanoparticles, or lipid-based delivery systems. Fiber, essential fatty acids, and micronutrients are absent at functional levels in this extract form.

Preparation & Dosage

No clinically studied dosage ranges for Curcumin-95 are detailed in the provided research. Studies on general curcumin use ≥95% standardized extracts, but specific ranges, standardization protocols, or forms are not quantified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Black pepper extract (piperine), phospholipids, omega-3 fatty acids, green tea extract, quercetin

Safety & Interactions

Curcumin is generally recognized as safe at doses up to 8 g/day in short-term studies, though gastrointestinal side effects including nausea, diarrhea, and stomach cramping are reported at higher doses. It inhibits CYP3A4 and CYP2C9 enzymes and P-glycoprotein, creating clinically relevant interactions with anticoagulants such as warfarin, antiplatelet drugs, and certain chemotherapy agents including docetaxel. Curcumin also exhibits mild antiplatelet activity and should be discontinued at least two weeks before surgery. Pregnant women should avoid therapeutic doses, as curcumin has demonstrated uterine-stimulating effects in animal models, though culinary amounts in food are considered safe.